Literature DB >> 21582856

3-exo-Chloro-8-oxabicyclo-[3.2.1]oct-6-ene-2,4-diol chloro-form 0.33-solvate.

Viktor A Tafeenko1, Leonid A Aslanov, Marina V Proskurnina, Sergei E Sosonyuk, Dmitrii A Khlevin.   

Abstract

The title compound, 3C(7)H(9)ClO(3)·CHCl(3), crystallizes with mol-ecules of 3-exo-chloro-8-oxabicyclo-[3.2.1]oct-6-ene-2,4-diol (A) and chloro-form in a 3:1 ratio, in the space group R3m. Mol-ecules of A straddle a crystallographic mirror plane, whereas the chloro-form mol-ecules (C and H atoms) lie additionally on the threefold axis. The mol-ecules of A are linked into right- and left-helical chains by means of O-H⋯O hydrogen bonds, thus forming columns running along the c axis. Six inter-penetrated columns form a channel in which the solvent mol-ecules (chloro-form) are located.

Entities:  

Year:  2009        PMID: 21582856      PMCID: PMC2969453          DOI: 10.1107/S1600536809021898

Source DB:  PubMed          Journal:  Acta Crystallogr Sect E Struct Rep Online        ISSN: 1600-5368


Related literature

Inositetriphosphates analogues are potential prospective anti­tumoral compounds, see: Piettre et al. (1997 ▶); Miller & Allemann (2007 ▶).

Experimental

Crystal data

3C7H9ClO3·CHCl3 M = 649.16 Hexagonal, a = 18.687 (5) Å c = 6.8723 (16) Å V = 2078.3 (9) Å3 Z = 3 Cu Kα radiation μ = 6.09 mm−1 T = 295 K 0.1 × 0.07 × 0.06 mm

Data collection

Enraf–Nonius CAD-4 diffractometer Absorption correction: ψ scan (North et al., 1968 ▶) T min = 0.530, T max = 0.694 1832 measured reflections 987 independent reflections 966 reflections with I > 2σ(I) R int = 0.036 2 standard reflections frequency: 120 min intensity decay: none

Refinement

R[F 2 > 2σ(F 2)] = 0.054 wR(F 2) = 0.168 S = 1.18 987 reflections 69 parameters 1 restraint H atoms treated by a mixture of independent and constrained refinement Δρmax = 0.28 e Å−3 Δρmin = −0.51 e Å−3 Absolute structure: Flack (1983 ▶), 481 Friedel pairs Flack parameter: −0.01 (2) Data collection: CAD-4 Software (Enraf–Nonius, 1989 ▶); cell refinement: CAD-4 Software; data reduction: XCAD4 (Harms & Wocadlo, 1995 ▶); program(s) used to solve structure: SHELXS97 (Sheldrick, 2008 ▶); program(s) used to refine structure: SHELXL97 (Sheldrick, 2008 ▶); molecular graphics: DIAMOND (Brandenburg, 2000 ▶); software used to prepare material for publication: WinGX (Farrugia, 1999 ▶). Crystal structure: contains datablocks I, global. DOI: 10.1107/S1600536809021898/si2178sup1.cif Structure factors: contains datablocks I. DOI: 10.1107/S1600536809021898/si2178Isup2.hkl Additional supplementary materials: crystallographic information; 3D view; checkCIF report
3C7H9ClO3·CHCl3Dx = 1.556 Mg m3
Mr = 649.16Melting point: decomposition K
Hexagonal, R3mCu Kα radiation, λ = 1.54184 Å
Hall symbol: R 3 -2"Cell parameters from 25 reflections
a = 18.687 (5) Åθ = 32–45°
c = 6.8723 (16) ŵ = 6.09 mm1
V = 2078.3 (9) Å3T = 295 K
Z = 3Prism, colourless
F(000) = 10020.1 × 0.07 × 0.06 mm
Enraf–Nonius CAD-4 diffractometer966 reflections with I > 2σ(I)
Radiation source: fine-focus sealed tubeRint = 0.036
graphiteθmax = 71.9°, θmin = 4.7°
Nonprofiled ω scansh = −22→0
Absorption correction: ψ scan (North et al., 1968)k = 0→22
Tmin = 0.530, Tmax = 0.694l = −8→8
1832 measured reflections2 standard reflections every 120 min
987 independent reflections intensity decay: none
Refinement on F2Hydrogen site location: inferred from neighbouring sites
Least-squares matrix: fullH atoms treated by a mixture of independent and constrained refinement
R[F2 > 2σ(F2)] = 0.054w = 1/[σ2(Fo2) + (0.021P)2 + 2.2041P] where P = (Fo2 + 2Fc2)/3
wR(F2) = 0.168(Δ/σ)max = 0.001
S = 1.18Δρmax = 0.28 e Å3
987 reflectionsΔρmin = −0.51 e Å3
69 parametersExtinction correction: SHELXL97 (Sheldrick, 2008), Fc*=kFc[1+0.001xFc2λ3/sin(2θ)]-1/4
1 restraintExtinction coefficient: 0.0016 (4)
Primary atom site location: structure-invariant direct methodsAbsolute structure: Flack (1983), 481 Friedel pairs
Secondary atom site location: difference Fourier mapFlack parameter: −0.01 (2)
Experimental. As the solvent molecules release from the crystal at ambient air, so the experiment was carried out from the crystal placed in a glass capillary.
Geometry. All esds (except the esd in the dihedral angle between two l.s. planes) are estimated using the full covariance matrix. The cell esds are taken into account individually in the estimation of esds in distances, angles and torsion angles; correlations between esds in cell parameters are only used when they are defined by crystal symmetry. An approximate (isotropic) treatment of cell esds is used for estimating esds involving l.s. planes.
Refinement. Refinement of F2 against ALL reflections. The weighted R-factor wR and goodness of fit S are based on F2, conventional R-factors R are based on F, with F set to zero for negative F2. The threshold expression of F2 > σ(F2) is used only for calculating R-factors(gt) etc. and is not relevant to the choice of reflections for refinement. R-factors based on F2 are statistically about twice as large as those based on F, and R- factors based on ALL data will be even larger.
xyzUiso*/Ueq
Cl10.29956 (13)0.14978 (7)0.6438 (3)0.0671 (7)
Cl20.61527 (5)0.38473 (5)0.7368 (3)0.0619 (6)
O10.3605 (3)0.0525 (2)0.3740 (6)0.0560 (10)
O20.5272 (3)0.26359 (14)0.3179 (9)0.0583 (13)
C10.3610 (3)0.18052 (16)0.4256 (8)0.0341 (12)
H10.32320.16160.31430.041*
C20.4122 (3)0.1378 (2)0.4156 (6)0.0397 (10)
H20.43930.14360.54140.048*
C30.4782 (3)0.1795 (3)0.2586 (8)0.0510 (12)
H30.51150.15270.24340.061*
C40.4419 (4)0.1856 (3)0.0684 (8)0.0543 (12)
H40.42280.1467−0.03110.065*
C50.66670.33330.654 (2)0.048 (3)
H50.66670.33330.51110.058*
H110.361 (4)0.024 (4)0.453 (10)0.063 (19)*
U11U22U33U12U13U23
Cl10.0535 (11)0.0777 (11)0.0619 (10)0.0268 (5)0.0216 (8)0.0108 (4)
Cl20.0497 (8)0.0497 (8)0.0932 (14)0.0300 (8)0.0052 (4)−0.0052 (4)
O10.077 (3)0.0298 (16)0.058 (2)0.0241 (18)−0.0182 (19)−0.0027 (15)
O20.026 (2)0.054 (2)0.085 (3)0.0128 (11)0.001 (2)0.0003 (11)
C10.026 (3)0.033 (2)0.040 (3)0.0132 (13)−0.002 (2)−0.0012 (11)
C20.039 (2)0.0310 (19)0.052 (2)0.0196 (17)−0.0126 (18)−0.0054 (17)
C30.039 (2)0.052 (3)0.071 (3)0.029 (2)0.004 (2)−0.003 (2)
C40.054 (3)0.061 (3)0.051 (2)0.031 (2)0.013 (2)0.000 (2)
C50.033 (3)0.033 (3)0.078 (8)0.0166 (16)0.0000.000
Cl1—C11.799 (6)C2—C31.526 (7)
Cl2—C51.759 (5)C2—H20.9800
O1—C21.420 (5)C3—C41.503 (8)
O1—H110.77 (7)C3—H30.9800
O2—C3i1.426 (6)C4—C4i1.320 (11)
O2—C31.426 (6)C4—H40.9300
C1—C21.524 (5)C5—Cl2ii1.759 (5)
C1—C2i1.524 (5)C5—Cl2iii1.759 (5)
C1—H10.9800C5—H50.9800
C2—O1—H11114 (5)O2—C3—C2105.7 (4)
C3i—O2—C3102.6 (5)C4—C3—C2111.9 (4)
C2—C1—C2i113.8 (5)O2—C3—H3111.8
C2—C1—Cl1109.8 (3)C4—C3—H3111.8
C2i—C1—Cl1109.8 (3)C2—C3—H3111.8
C2—C1—H1107.7C4i—C4—C3107.6 (3)
C2i—C1—H1107.7C4i—C4—H4126.2
Cl1—C1—H1107.7C3—C4—H4126.2
O1—C2—C1110.1 (4)Cl2ii—C5—Cl2iii110.0 (4)
O1—C2—C3110.7 (4)Cl2ii—C5—Cl2110.0 (4)
C1—C2—C3108.8 (4)Cl2iii—C5—Cl2110.0 (4)
O1—C2—H2109.1Cl2ii—C5—H5108.9
C1—C2—H2109.1Cl2iii—C5—H5108.9
C3—C2—H2109.1Cl2—C5—H5108.9
O2—C3—C4103.3 (4)
D—H···AD—HH···AD···AD—H···A
O1—H11···O1iv0.77 (7)1.98 (7)2.723 (3)162 (7)
Table 1

Hydrogen-bond geometry (Å, °)

D—H⋯AD—HH⋯ADAD—H⋯A
O1—H11⋯O1i0.77 (7)1.98 (7)2.723 (3)162 (7)

Symmetry code: (i) .

  3 in total

Review 1.  myo-Inositol monophosphatase: a challenging target for mood stabilising drugs.

Authors:  D J Miller; R K Allemann
Journal:  Mini Rev Med Chem       Date:  2007-02       Impact factor: 3.862

2.  A short history of SHELX.

Authors:  George M Sheldrick
Journal:  Acta Crystallogr A       Date:  2007-12-21       Impact factor: 2.290

3.  Monoaryl- and bisaryldihydroxytropolones as potent inhibitors of inositol monophosphatase.

Authors:  S R Piettre; C André; M C Chanal; J B Ducep; B Lesur; F Piriou; P Raboisson; J M Rondeau; C Schelcher; P Zimmermann; A J Ganzhorn
Journal:  J Med Chem       Date:  1997-12-19       Impact factor: 7.446

  3 in total
  1 in total

1.  (1R,2R,3R,4S,5S)-3-Methyl-8-oxa-bicyclo-[3.2.1]oct-6-ene-2,4-diyl diacetate.

Authors:  Viktor A Tafeenko; Leonid A Aslanov; Marina V Proskurnina; Sergei E Sosonyuk; Dmitrii A Khlevin
Journal:  Acta Crystallogr Sect E Struct Rep Online       Date:  2011-07-23
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.